Merck & Co., Inc. MRK

Set alert

Price alert · MRK

All alert types
148.36 USD -1.16 -0.78%

At close · Nov 2

148.36 0.00 0.00%

After hours · Nov 2, 6:49 PM ET

Bid
148.45 × 400
Ask
148.46 × 100
147.12 Day range 150.25
82.01 52-week range 156.92
YTD
+40.95%
1 year
+72.55%
Open
148.82
Prev close
149.52
Mkt cap
366.03B
Vol
9.10M
Avg vol
10.36M
EPS
0.99
P/E
149.86
Div yield
2.27%
More statistics
Low
147.12
High
150.25
Forward P/E
16.34
Beta
0.12
Short ratio
2.68
Inst. own
82.88%
Dividend
3.40
Ex-div date
Sep 14, 2026
Earnings
Feb 2, 2027
50-d avg
146.86
200-d avg
126.71
1y target
159.91

1M chart

Chart tools
Interval

Events in this range
  • Oct 12, 2026Rating: Citigroup · Neutral → Neutral
  • Oct 26, 2026Rating: Barclays · Overweight → Overweight
  • Oct 29, 2026Earnings: 2.49; estimate 2.09; surprise 19.14%
  • Oct 30, 2026Rating: Guggenheim · Buy → Buy
  • Oct 30, 2026Rating: RBC Capital · Sector Perform → Sector Perform
  • Oct 30, 2026Rating: JP Morgan · Overweight → Overweight
  • Nov 2, 2026Rating: Cantor Fitzgerald · Neutral → Neutral
Signals (18)
NameDateAgo
SMA: BullishOct 30, 20263 days ago
MACD: Buy SignalOct 30, 20263 days ago
SMA: BullishOct 29, 20264 days ago
MACD: Sell SignalOct 26, 20261 week ago
SMA: BearishOct 23, 20261 week ago
SMA: BearishOct 23, 20261 week ago
SMA: BullishOct 20, 20261 week ago
SMA: BullishOct 20, 20261 week ago
MACD: Buy SignalOct 20, 20261 week ago
SMA: BearishOct 19, 20262 weeks ago
SMA: BearishOct 19, 20262 weeks ago
SMA: BullishOct 14, 20262 weeks ago
SMA: BullishOct 14, 20262 weeks ago
SMA: BearishOct 13, 20262 weeks ago
SMA: BearishOct 13, 20262 weeks ago
SMA: BullishOct 9, 20263 weeks ago
SMA: BullishOct 9, 20263 weeks ago
SMA: BearishOct 5, 20264 weeks ago

Key statistics

Market cap
366.35B
Enterprise value
415.71B
Trailing P/E
149.99
Forward P/E
16.34
PEG ratio
2.82
Price / sales
5.44
Price / book
8.74
EPS (TTM)
0.99
Beta
0.12
Dividend yield
2.27%
Payout ratio
266.67%
Profit margin
3.64%
Revenue (TTM)
67.38B
Revenue growth
4.70%
Free cash flow
0
Total cash
7.14B
Total debt
53.91B
Return on equity
0.00%
Shares outstanding
2.47B
Short % of float
1.09%
50-day average
146.86
200-day average
126.71

Analyst view

Consensus: buy

Buy
Price target (mean) 159.91 +7.8% upside
Target (low)
105.00
Target (mean)
159.91
Target (high)
186.00
Ratings (0m) 28 19 buy · 9 hold · 0 sell
  • Strong buy5
  • Buy14
  • Hold9
  • Sell0
  • Strong sell0

Next earnings

Feb 2, 2027

Expected Feb 2, 2027. Consensus EPS estimate 1.79.

Earnings history

Financials — quick view

All financials
MRK Revenue — quarterly 16.61B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MRK Net income — quarterly -1.33B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MRK EPS — quarterly -0.54
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

MRK recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 2, 2027Dec 30, 20261.79———
Oct 29, 2026Sep 30, 20262.092.49+0.40+19.14%
Aug 4, 2026Jun 30, 2026-0.27049-0.13+0.14+51.94%
Apr 30, 2026Mar 31, 2026-1.47-1.28+0.19+12.93%
Feb 3, 2026Dec 31, 20252.012.04+0.03+1.49%
Oct 30, 2025Sep 30, 20252.362.58+0.22+9.32%

Upgrades / downgrades

MRK analyst upgrades and downgrades
DateFirmActionFromTo
Nov 2, 2026Cantor FitzgeraldmainNeutralNeutral
Oct 30, 2026JP MorganmainOverweightOverweight
Oct 30, 2026RBC CapitalmainSector PerformSector Perform
Oct 30, 2026GuggenheimmainBuyBuy
Oct 26, 2026BarclaysmainOverweightOverweight
Oct 12, 2026CitigroupmainNeutralNeutral

About Merck & Co., Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Website
merck.com

News

Your note

Sign in to keep a note on MRK — it syncs with the Stock Master app.

Insider holders

MRK insider holders
InsiderRelationLatest transactionDateShares held
CHATTOPADHYAY SANATOfficerConversion of Exercise of derivative securityApr 28, 2026200,675
DAVIS ROBERT MChief Executive OfficerConversion of Exercise of derivative securityApr 28, 2026450,351
DELUCA RICHARD ROBERT JR.OfficerSaleAug 11, 2026110,167
GUINDO CHIRFIOfficerSaleAug 12, 202636,613
LI DEAN YOfficerConversion of Exercise of derivative securityApr 28, 202694,431
LITCHFIELD CAROLINEChief Financial OfficerConversion of Exercise of derivative securityApr 28, 202692,300

Institution ownership

MRK institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.20%226,999,83733.71BJun 29, 2026
Vanguard Capital Management LLC6.54%161,323,17423.95BJun 29, 2026
State Street Corporation4.88%120,413,25617.88BJun 29, 2026
Wellington Management Group, LLP3.50%86,249,28312.81BJun 29, 2026
Vanguard Portfolio Management LLC2.75%67,738,96910.06BJun 29, 2026
Geode Capital Management, LLC2.46%60,744,2149.02BJun 29, 2026

Fund ownership

MRK fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.18%78,411,37411.64BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%63,996,8849.50BJun 29, 2026
SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF1.47%36,188,6065.37BAug 30, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%32,874,3674.88BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%32,060,5434.76BAug 30, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.24%30,514,3124.53BSep 29, 2026